Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Can drugs fix the UK’s adolescent obesity crisis?

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes

The Guardian - UK

Children could be prescribed weight-loss jabs on the NHS

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17

The Guardian - UK

Viral Weight Loss Drugs Like Ozempic and Wegovy Sell For $10,000. Here's Why.

Viral demand for the shots producing dramatic weight loss has sent prices upward.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Doctors issue urgent warning over diabetes drug Ozempic being sold on Facebook Marketplace

The alert comes after an increased number of social media posts, in which users are marketing the drug as a rapid weight loss solution

Chronicle Live

Social Media adds to weight loss craze

GLP-1 agonists are a class of weight loss drug that is going viral on social media — but misinformation is rife

Salon

A ‘skinny jab’ is no quick fix for obesity – and no excuse to let junk food companies off the hook

Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor

The Guardian - UK

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Social media is fueling enthusiasm for new weight loss drugs. Are regulators watching?

Suzette Zuena is her own best advertisement for weight loss.

Tribune News Service

Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook

Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments.

Investors Business Daily

Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $2.7 Billion Deal

Novo Nordisk stock popped Wednesday after the drugmaker inked a $2.7 billion deal that bolsters its diabetes and obesity treatments.

Investors Business Daily

Experts warn new weight loss medications carry long-term concerns

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

Chicago Sun-Times

So, is Wegovy the same as Ozempic? Your need-to-knows about the controversial over-the-counter weight loss drugs

Two experts explain.

Marie Claire

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

The Guardian - UK

EU backs use of Novo Nordisk's weight loss drug in adolescents

The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk's weight loss drug in adolescents aged 12 years and older.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

How Investors are Capitalizing on the Ozempic and Wegovy Craze

Ozempic and Wegovy started as injectable diabetes treatments. But now, these “appetite suppressants” are being touted as miracle weight loss drugs.

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

StockNews.com

Stay Forever Young With These 3 Pharmaceutical Stocks

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

Evening Standard

WHO to consider adding obesity drugs to ‘essential’ medicines list

A panel of advisers to the WHO will review requests for drugs to be included next month

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients.

ABC News

Relief for diabetes sufferers with fast-acting insulin Fiasp to remain on PBS until September

Fast-acting insulin Fiasp has been a "game changer" for Daniel Webb in managing his type 1 diabetes. The drug was about to be removed from the PBS, but a temporary solution has been found.

The Guardian - UK

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

Los Angeles Times

Newsom announces $50 million contract to make California’s own brand of insulin

LOS ANGELES — California Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.

The Guardian - UK

‘Skinny jab’ drug firm facing fresh inquiries after ‘serious breaches’ of industry code

Pharmaceutical company behind blockbuster diet jab Wegovy confronts crises on multiple fronts, amid scrutiny of UK activities

AFP

Sanofi, joining other drug makers, slashes US insulin price

New York (AFP) - French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers.

Axios

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations